
|Videos|April 14, 2023
Understanding and Mitigating the Cardiometabolic Risks of ADT
Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems
2
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
3
EV plus pembro approval reframes first conversation in MIBC diagnosis
4
Genomic Prostate Score may help refine risk assessment in localized prostate cancer
5














